Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up

详细信息    查看全文

• 作者：M.E. Evangelopoulos^a ; ^{evangelopoulos@yahoo.gr} ; E. Andreadou^a ; G. Koutsis^a ; V. Koutoulidis^b ; M. Anagnostouli^a ; P. Katsika^a ; D.S. Evangelopoulos^c ; I. Evdokimidis^a ; C. Kilidireas^a
• 关键词：Neuromyelitis optica ; Neuromyelitis optica spectrum disorders ; Rituximab treatment
• 刊名：Journal of the Neurological Sciences
• 出版年：2017
• 出版时间：15 January 2017
• 年：2017
• 卷：372
• 期：Complete
• 页码：92-96
• 全文大小：373 K
• 卷排序：372

文摘

Neuromyelitis optinca (NMO) represents a serious demyelinating disease of the CNS The disease selectively attacks the spinal cord and optic nerve. Early differential diagnosis from multiple sclerosis is of vital importance Five patients Rituximab treatment of NMO & NMOSD patients improves disability and relapse rate without significant adverse effects.